This secondary analysis of the TRIANGLE trial investigated the efficacy and toxicity of rituximab maintenance added to ibrutinib-based regimens. Rituximab maintenance significantly prolonged progression-free survival across all treatment arms compared to no rituximab maintenance. While rituximab maintenance led to a higher incidence of grade 3-5 infectious toxicities, there was no increase in treatment-related deaths.
Study
|
Secondary analysis of randomized, open-label, phase 3 TRIANGLE study |
| Untreated mantle cell lymphoma in remission after ibrutinib-containing induction and/or ASCT |
| Rituximab maintenance (RM) vs no RM in ibrutinib-containing therapy without ASCT (Arm I), ibrutinib-containing therapy with ASCT (Arm A + I), and conventional therapy with ASCT (Arm A)
|
Efficacy
|
4 yr PFS (Arm I): 85% vs 73% (RM vs. no RM) (HR 0.48 [0.29-0.80]) |
| 4 yr OS (Arm I): 91% vs 86% (HR 0.60 [0.27-1.35]) |
| 4 yr PFS (Arm A + I): 90% vs 75% (HR 0.27 [0.14-0.53]) |
| 4 yr OS (Arm A + I): 94% vs 87% (HR 0.51 [0.19-1.38]) |
| 4 yr PFS (Arm A): 82% vs 59% (HR 0.41 [0.22-0.74]) |
| 4 yr OS (Arm A): 87% vs 84% (HR 0.81 [0.36-1.81])
|
Safety
|
Any grade 3 to 5 AEs: 68% vs 50% (Arm I); 79% vs 74% (Arm A + I); 42% vs 26% (Arm A) |
| Infections and infestations: 34% vs 11% (Arm I); 41% vs 18% (Arm A + I); 19% vs 1% (Arm A))
|
J Clin Oncol 2026;00:1-8
http://doi.org/10.1200/JCO-26-00705
Reviewed by Ulas D. Bayraktar, MD on Aug 20, 2026
